Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Kumiko Nagashima"'
Autor:
Cloud P Paweletz, Jannik N Andersen, Roy Pollock, Kumiko Nagashima, Mansuo L Hayashi, Shangshuan U Yu, Hongbo Guo, Ekaterina V Bobkova, Zangwei Xu, Alan Northrup, Peter Blume-Jensen, Ronald C Hendrickson, An Chi
Publikováno v:
PLoS ONE, Vol 6, Iss 10, p e26459 (2011)
Pharmacodynamic (PD) biomarkers are an increasingly valuable tool for decision-making and prioritization of lead compounds during preclinical and clinical studies as they link drug-target inhibition in cells with biological activity. They are of part
Externí odkaz:
https://doaj.org/article/ecc88f9d2bf143f09228d27bcd3a4329
Autor:
Yan Wang, Erick J. Morris, Richard E. Middleton, Paul T. Kirschmeier, Leigh Zawel, Cynthia Seidel-Dugan, Pasi A. Jánne, Kwok-Kin Wong, Kumiko Nagashima, Heather Hirsch, Steven Ripley, Chris Hulton, Weiqun Zhang, Rossana Chung, Stephen Wu, Peter Strack, Thi T. Nguyen, Brian Dolinski, Jongwon Lim, Rafael Fernandez, Haiyan Yan, Qi Pan, Asli Muvaffak
PDF file - 1334KB, S1. IC50 values of TBK1 inhibitors Compound number 5, Compound number 4 and Compound number 3 from the selected PDAC, colorectal cancer and NSCLC cancer cell lines using are shown. Table 1S. List of shRNAs Targeting TBK1 Table 2S.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::98442b5d4353d94a24d08eb4fa097ec2
https://doi.org/10.1158/1541-7786.22511083
https://doi.org/10.1158/1541-7786.22511083
Autor:
Manfred Kraus, Jannik N. Andersen, Peter Blume-Jensen, Nancy Kohl, Victoria Richon, Giulio Draetta, Martin L. Scott, Roderick T. Bronson, Shailaja Kasibhatla, Ekaterina V. Bobkova, Alan Northrup, Thomas F. Vogt, Myung K. Shin, Melissa Hurd, Paula Andrade, Erica Leccese, Minilik Angagaw, Nirah H. Shomer, Diana Gargano, Alessandra Di Bacco, Yusuf Erkul, Erin O'Hare, Kumiko Nagashima, Kun Hu, Yamicia Connor, Brian Dolinski, Kaiko Kunii, Heike Keilhack, Katharine Ellwood-Yen
Supplementary Figures 1-4 from PDK1 Attenuation Fails to Prevent Tumor Formation in PTEN-Deficient Transgenic Mouse Models
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::828919a62a5a02040e157eb5ac219fb4
https://doi.org/10.1158/0008-5472.22390089
https://doi.org/10.1158/0008-5472.22390089
Autor:
D. Gary Gilliland, Jannik N. Andersen, Peter Strack, Kumiko Nagashima, Pamela M. Carroll, Erica M. Cook, Thi D.T. Nguyen, Marc Ferrer, Erick J. Morris, Bryan Severyn, Andrey Loboda, Jeff Hermes, Michelle A. Cleary, Sriram Sathyanarayanan, Bill Arthur, Yair Benita, Lixia Li, G. Naumov, Michael D. Altman, James Watters, Matthew Tudor
Publikováno v:
SLAS Discovery. 21:989-997
The RAS-MAPK pathway controls many cellular programs, including cell proliferation, differentiation, and apoptosis. In colorectal cancers, recurrent mutations in this pathway often lead to increased cell signaling that may contribute to the developme
Autor:
Michael Briskin, V Cortez-Retamozo, Igor Feldman, Mohammad Zafari, R Larson, Kumiko Nagashima, Robert Mabry, Jeffrey W. Smith, T Novorantseva, Shaffer, S Sathyanaryananan
Publikováno v:
Cancer Research. 76:P2-11
B7-H4 (VTCN1, B7x, B7S1) is a transmembrane protein belonging to the B7 family of costimulatory proteins and has been shown to inhibit T cell proliferation, cytokine secretion, and cytotoxic lymphocyte (CTL) induction. B7-H4 expressed on tumor cells
Autor:
Youyuan Xu, Cloud P. Paweletz, Maciej Wiznerowicz, Victoria M. Richon, Sanjeev Munshi, Brian Dolinski, Kumiko Nagashima, Anke Klippel, Sujal V. Deshmukh, Peter Blume-Jensen, Bo-Sheng Pan, Jannik N. Andersen, Alan B. Northrup, Timothy Allison, Alexander A. Szewczak, Zangwei Xu, Manfred Kraus, Heike Keilhack, Sriram Sathyanarayanan, Youwei Yan, Albert H. Y. Chen, Uwe Mueller, Lixia Li, An Chi, Thi D.T. Nguyen, Ekaterina V. Bobkova, Roy M. Pollock, Bart Lutterbach, Stuart D. Shumway
Publikováno v:
Journal of Biological Chemistry. 286:6433-6448
Phosphoinositide-dependent kinase 1 (PDK1) is a critical activator of multiple prosurvival and oncogenic protein kinases and has garnered considerable interest as an oncology drug target. Despite progress characterizing PDK1 as a therapeutic target,
Autor:
Ilona Kariv, Alan B. Northrup, Dongyu Sun, Thomas S. Rush, Kumiko Nagashima, Ekaterina V. Bobkova, Zangwei Xu, Jannik N. Andersen
Publikováno v:
SLAS Discovery. 14:1257-1262
The PI3K/Akt signaling pathway plays a key role in cancer cell growth, survival, and tumor angiogenesis. 3-Phosphoinositide-dependent protein kinase 1 (PDK1) is a Ser/Thr protein kinase, which catalyzes the phosphorylation of a conserved residue in t
Autor:
Yonghao Yu, Ronald C. Hendrickson, Rana Anjum, Kumiko Nagashima, Manfred Kraus, Kazuishi Kubota, John Rush, Ryan C. Kunz, Jannik N. Andersen, Cloud P. Paweletz, Steven P. Gygi, Heike Keilhack, Chin-Lee Wu, Judit Villén, Adam S. Feldman, Stefan Krauss
Publikováno v:
Nature Biotechnology. 27:933-940
Constitutive activation of one or more kinase signaling pathways is a hallmark of many cancers. Here we extend the previously described mass spectrometry-based KAYAK approach by monitoring kinase activities from multiple signaling pathways simultaneo
Autor:
Ethan P. Grant, Andrew Bielecki, Hua Yang, Danyi Wen, Bruce Jaffee, Yajun Xu, Christopher Fraser, Chris Simpson, Michael E. Hepperle, Tim Ocain, Kumiko Nagashima, Vito G. Sasseville, Gerry Harriman
Publikováno v:
Blood. 107:4266-4273
The transcription factor NF-κB plays a central role in regulating inflammation and apoptosis, making it a compelling target for drug development. We identified a small molecule inhibitor (ML120B) that specifically inhibits IKKβ, an Ikappa-B kinase
Autor:
Davinder Singh Gill, Jean-Luc Villeval, Martine Jandrot-Perrus, Ximing Xiong, Andrew D. J. Goodearl, James R. Tonra, Kevin McDonald, Ming D. Qian, Kumiko Nagashima
Publikováno v:
Human Antibodies. 11:97-105
Glycoprotein VI is a type I membrane protein identified as a key platelet receptor for collagen. In vitro binding of the GPVI receptor with collagen leads to activation and ultimately to aggregation of platelets. In vivo, GPVI-collagen interactions c